Modern VaccinesAdjuvants Formulation

15-17 May 2013, CHUV, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 17th May

SESSION 9:
ADJUVANTS

Moderator: Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

09.00-09.30
‘Biomarkers of experimental mucosal adjuvants’
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

09.30-10.00
‘Complement as natural adjuvant’
Martin Bachmann (University of Zurich, Zurich, Switzerland)

10.00-10.20
‘A novel combination adjuvant for mucosal vaccination against respiratory syncytial virus’
Sylvia van Drunen Little-van den Hurk, R. Garg, R. Brownlie, L. Latimer, W. Connor, E. Simko, V. Gerdts, L.A. Babiuk and A. Potter (VIDO-Intervac, University of Saskatchewan, Saskatoon, S7N 5E3, Canada)

10.20-10.40
‘Novel vaccine adjuvants for induction of cellular and humoral immunity’
Sandrine Crabe and Vincent Serra (Wittycell SA, Reims, France)

10.40-11.10
Coffee Break & Posters

SESSION 10:
TLRs and CLRs & DENDRITIC CELLS

Moderator: Christopher Fox (IDRI, Seattle, Washington, USA)

11.10-11.40
In vitro evaluation of TLR4 agonist activity: Formulation effects’
Christopher Fox (IDRI, Seattle, Washington, USA)

11.40-12.00
‘Ligands for toll-like and C-type lectin receptors for targeting and activating dendritic cells’
Kenneth C. McCullough, Ranji Sharma, Brigitte Herrmann, Evgeniya Rapoport, Nicolai Bovin, Isabelle Bassi, Panagiota Milona, Thomas Demoulins and Arin Ghasparian (Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

12.00-12.20
‘Dendritic cell targeting by nanogels: influence of surface decoration’
L.J. Thomann-Harwood, C.A. Schuetz, B.H. Herrmann, P. Kaeuper, N. Rossi and K.C. McCullough (Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

12.20-13.30
Lunch Break & Posters

SESSION 11:
ADJUVANTS FOR THERAPEUTIC VACCINES

Moderator: Adriana Baz Morelli (CSL Limited, Parkville, Victoria, Australia)

13.30-14.00
‘Enhancing the efficacy of cancer therapeutic monoclonal antibodies with ISCOMAB formulation: a technology based upon ISCOMATRIX adjuvant’
Adriana Baz Morelli (CSL Limited, Parkville, Victoria, Australia)

14.00-14.20
‘Delayed type hypersensitivity reactions correlating with overall survival in patients with metastatic melanoma, after vaccination with peptides, CpG and Montanide’
Daniel E. Speiser (University of Lausanne, Lausanne, Switzerland)

14.20-14.40
‘Montanide ISA 51 VG and Montanide ISA 720 VG, adjuvants dedicated to therapeutic vaccines’
Stephane Ascarateil (SEPPIC, Paris, France)

14.40-15.00
‘Targeting the tumor-draining lymph node with a nanoparticle vaccine enhances its therapeutic efficacy as cancer immunotherapy’
Laura Jeanbart, Patricia Corthésy, Marie Ballester, Alexandre de Titta, André van der Vlies, Jeffrey A. Hubbell and Melody A. Swartz (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)

15.00-15.20
‘RNAdjuvant®, a novel RNA-based immunomodulator, combines strong immunostimulatory capacities with a favourable safety profile’
Regina Heidenreich, Benjamin Petsch, Edith Jasny, Mariola Fotin-Mleczek, Patrick Baumhof, Birgit Scheel, Söhnke Voss and Karl-Josef Kallen (CureVac GmbH, Tubingen, Germany)

15.20-15.35
Tea Break & Poster Breakdown

SESSION 12:
REGULATORY & SAFETY ISSUES

Moderator: Geert Vanden Bossche (UNIVAC llc., Seattle, Washington, USA)

15.35-16.05
‘Vaccine CMC – anticipating the regulator’
Brijesh Patel (MHRA, London, UK)

16.05-16.35
‘Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation’
Wim Van Molle, K. Brusselmans, L. Tesolin and G. Waeterloos (Scientific Institute of Public Health, Brussels, Belgium)

16.35
Closing Remarks & Departure

Geert Vanden Bossche (UNIVAC llc., Seattle, Washington, USA)

* This final programme is correct at the time of publishing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final conference MVAF 2013 conference programme.

 

MVAF 2013 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2013 Sponsors

  • Viscogel
  • Vironova
  • Vedantra Pharmaceuticals
  • Aldevron
  • Dynavax
  • Mucosis
  • Pfizer
  • Inovio
  • Izon
  • IDRI
  • Sanofi Pasteur
  • Novartis Vaccines
  • Seppic
  • CSL
  • European Adjuvant Advisory Committee
  • Univac
  • Intercell
  • Vaccine Formulation Laboratory
  • Immune Solutions
  • DNA Vaccine
  • Immune Design
  • Pharvat
  • Retroscreen Virology
  • Wittycell
  • Brenntag

MVAF 2013 Downloads

MVAF 2013 Leaflet

MVAF 2013 Mailing List

Name
E-mail Address
What is 1+4-2?